Benchmark Initiates Coverage On Belite Bio with Buy Rating, Announces Price Target of $57

Benchmark analyst Bruce Jackson initiates coverage on Belite Bio (NASDAQ:BLTE) with a Buy rating and announces Price Target of $57.

Benchmark analyst Bruce Jackson initiates coverage on Belite Bio (NASDAQ:BLTE) with a Buy rating and announces Price Target of $57.

Total
0
Shares
Related Posts